Filing Flows › Comparisons › ALKS vs MDGL
Alkermes vs Madrigal Pharmaceuticals: ALKS and MDGL compared
Alkermes is the larger company: $480M of revenue in its latest quarter (Q3 2026) against $431M for Madrigal Pharmaceuticals (Q3 2026). Madrigal Pharmaceuticals is growing faster (+50% against +22% a year earlier). Madrigal Pharmaceuticals is more profitable, with an operating margin of 13.0% against 7.5%.
Where the money goes: ALKS and MDGL
Alkermes (ALKS) · Q3 2026
Alkermes, Q3 2026: revenue $480M (+22% year over year), operating margin 7.5%, net earnings $16.3M, operating cash flow $93.5M. The chart follows the revenue to costs, profit and cash.
Madrigal Pharmaceuticals (MDGL) · Q3 2026
Madrigal Pharmaceuticals, Q3 2026: revenue $431M (+50% year over year), operating margin 13.0%, net earnings $55.4M, operating cash flow $121M. The chart follows the revenue to costs, profit and cash.
| Alkermes (ALKS) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $480M | $431M |
| Revenue growth, Y/Y | +22% | +50% |
| Operating margin | 7.5% | 13.0% |
| Net earnings | $16.3M | $55.4M |
| Net margin | 3.4% | 12.9% |
| Operating cash flow | $93.5M | $121M |
| Free cash flow | $90.1M | $117M |
| Market value | $8.1B | $12.1B |
| Analysts’ mean target | $57.74 | $688.94 |
Where the revenue comes from
Alkermes
- Product: $417M (87%)
- Royalty: $63.2M (13%)
Questions
Which is bigger, Alkermes or Madrigal Pharmaceuticals?
Alkermes is the larger company: $480M of revenue in its latest quarter (Q3 2026) against $431M for Madrigal Pharmaceuticals (Q3 2026).
Is Alkermes or Madrigal Pharmaceuticals growing faster?
Madrigal Pharmaceuticals is growing faster (+50% against +22% a year earlier).
Which is more profitable, Alkermes or Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals is more profitable, with an operating margin of 13.0% against 7.5%.
More: Alkermes earnings · how Alkermes makes money · Madrigal Pharmaceuticals earnings · how Madrigal Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.